Triple negative breast cancer

Common Name(s)

Triple negative breast cancer

Triple negative breast cancer (TNBC) describes any type of breast cancer that lacks three types of receptors that are often used for targeted treatments. These three types of receptors are estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2/neu). These receptors are involved in cell signaling and are found on affected cells in breast cancer that is not TNBC. There are different forms of TNBC, and about 10-20 percent of women who are diagnosed with breast cancer have a TNBC form.

Women who are younger in age, African American or Hispanic, and/or have mutations in the BRCA1 gene are more likely to have TNBC. TNBC often spreads more quickly than other types of breast cancer and presents a higher risk of coming back or recurring, especially in the first few years after treatment. After the first 3-5 years following treatment, the risk of recurrence of TNBC matches that of non-TNBC.

TNBC is diagnosed by taking a biopsy, or tissue sample, of the cancer. TNBC is less likely to respond to hormonal treatments but often does respond well to chemotherapy, radiation therapy, and surgery. If you have been diagnosed with TNBC, talk to your doctor about the most current treatment options. In addition, a genetic counselor can help discuss inheritance and risks to other family members. Support groups are a good source of information and can connect you with others who have been affected by breast cancer.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

http://www.bcconnections.org

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Triple negative breast cancer" returned 808 free, full-text research articles on human participants. First 3 results:

Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC).
 

Author(s): Fei Ma, Huihui Li, Yiqun Li, Xiaoyan Ding, Haijuan Wang, Ying Fan, Chen Lin, Haili Qian, Binghe Xu

Journal: Medicine (Baltimore). 2017 Apr;96(14):e6561.

 

Triple negative breast cancer (TNBC) is a subset of breast cancer that is highly aggressive and has a poor prognosis. Meanwhile, cancer stem cells (CSCs) are also characterized by a strong tumorigenic potential, which might be partly responsible for the aggressive behavior of TNBC. ...

Last Updated: 6 Apr 2017

Go To URL
Epidemiological and survival analysis of triple-negative breast cancer cases in a retrospective multicenter study.
 

Author(s): R Sarin, L Khandrika, Rnm Hanitha, A Avula, M Batra, S Kaul, H Raj, S Shivkumar, S Gupta, E Khan, Tps Bhandari, Svss Prasad, V A Reddy, G Swarnalata, M Bakre, S Chatterjee, J Jain

Journal: Indian J Cancer. ;53(3):353-359.

 

This is a retrospective study with data collected from breast cancer cases from five major Apollo Hospitals across India, as part of a biobanking process. One aspect of our study focused specifically on data from triple-negative breast cancer (TNBC) cases. The aim of this study was ...

Last Updated: 28 Feb 2017

Go To URL
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
 

Author(s): Gerardo Botti, Francesca Collina, Giosuè Scognamiglio, Federica Rao, Valentina Peluso, Rossella De Cecio, Michela Piezzo, Gabriella Landi, Michelino De Laurentiis, Monica Cantile, Maurizio Di Bonito

Journal:

 

Triple Negative Breast Cancers (TNBC) subtype is an aggressive disease with poor clinical outcome. The only treatment available is surgery followed by chemotherapy or radiotherapy. Programmed death-ligand 1 (PD-L1) is a trans-membrane protein expressed on a wide variety of cells including ...

Last Updated: 23 Feb 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Triple negative breast cancer" returned 58 free, full-text review articles on human participants. First 3 results:

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
 

Author(s): Carey K Anders, Vandana Abramson, Tira Tan, Rebecca Dent

Journal: Am Soc Clin Oncol Educ Book. 2016 ;35():34-42.

 

Triple-negative breast cancer (TNBC) is clinically defined as lacking expression of the estrogen receptor (ER), progesterone receptor (ER), and HER2. Historically, TNBC has been characterized by an aggressive natural history and worse disease-specific outcomes compared with other ...

Last Updated: 2 Jun 2016

Go To URL
Recent Progress in Triple Negative Breast Cancer Research.
 

Author(s): Fatima Zahra Mouh, Mohammed El Mzibri, Meriem Slaoui, Mariam Amrani

Journal: Asian Pac. J. Cancer Prev.. 2016 ;17(4):1595-608.

 

Triple-negative breast cancer (TNBC) is defined as a type of breast carcinoma that is negative for expression of oestrogene and progesterone hormone receptors (ER, PR) and HER2. This form of breast cancer is marked by its aggressiveness, low survival rate and lack of specific therapies. ...

Last Updated: 25 May 2016

Go To URL
Role of the androgen receptor in triple-negative breast cancer.
 

Author(s): Murtuza Rampurwala, Kari B Wisinski, Ruth O'Regan

Journal: Clin Adv Hematol Oncol. 2016 Mar;14(3):186-93.

 

Triple-negative breast cancer (TNBC) is an aggressive disease with outcomes inferior to those of other breast cancer subtypes. No targeted therapies are currently approved for TNBC, and newer treatment approaches are critically needed. It is increasingly recognized that TNBC is a ...

Last Updated: 9 Apr 2016

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
 

Status: Available

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 6 Oct 2010

Go to URL
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 6 Sep 2016

Go to URL
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 22 May 2017

Go to URL